$20M Series A

Building the first clinically-validated, dependency-aware longevity platform

The Opportunity

Market Size

$600B+

Global longevity economy by 2030. Current market is fragmented, unvalidated, and lacks scientific rigor.

  • $280B — Anti-aging supplements
  • $190B — Wellness and preventive care
  • $130B — Age-related therapeutics

Competitive Advantage

We're the only company with a mathematically-gated protocol.

  • Competitors: Sell individual compounds with no sequencing logic
  • We: Deliver state-dependent protocols with transition criteria
  • Moat: 6 framework papers, clinical validation, IP on dependency gating
  • Category creation: We define "dependency-aware longevity"

Why Now?

Epigenetic Clocks

Validated biomarkers for biological age make clinical trials feasible

Consumer Demand

Educated biohackers want science-backed protocols, not influencer stacks

Regulatory Pathway

FDA considering aging as indication opens path to approval

Use of Funds

$8M
40%

Clinical Validation

  • Phase I/II trials
  • Biomarker tracking
  • Safety monitoring
  • Long-term follow-up
$5M
25%

Platform Development

  • AI state monitoring
  • Wearable integration
  • Personalization engine
  • Data infrastructure
$4M
20%

Regulatory

  • FDA pathway
  • Clinical governance
  • Compliance systems
  • IRB management
$2M
10%

Category Leadership

  • Research publication
  • Education content
  • Ecosystem growth
  • Conference presence
$1M
5%

Team

  • Core scientific team
  • Clinical operations
  • Engineering hires
  • Operational support

Business Model

Phase 1: Clinical Program (2026-2028)

Physician-supervised implementation

  • Target: 500 participants in year 1
  • Revenue: $15K-25K per participant annually (comprehensive monitoring + protocols)
  • Projected Revenue: $7.5M-12.5M in year 1
  • Margin: 60% (after clinical, monitoring, physician costs)

Phase 2: Platform Scale (2029+)

AI-driven personalization at scale

  • Target: 10,000+ participants by year 3
  • Subscription: $500-1,000/month (monitoring + protocols + physician access)
  • Projected Revenue: $60M-120M ARR by year 3
  • Margin: 75% at scale (software + supply chain efficiency)

Revenue Streams

60%

Protocol subscriptions (recurring)

25%

Biomarker testing and monitoring

10%

Physician network fees

5%

Data licensing (pharma partnerships)

Team

MS

Mullo Saint

Founder & CEO

Author of Principia Sanitatis. Published framework papers at American Longevity Science. Background in systems biology and longevity research.

TBD

Chief Scientific Officer

Position Open

Seeking PhD with clinical trial experience in aging or metabolic interventions. Background in systems biology preferred.

TBD

VP Clinical Operations

Position Open

Experienced clinical operations leader with FDA regulatory background. Multi-site trial management required.

Advisory Board (Forming)

Assembling world-class advisors in longevity research, clinical development, regulatory strategy, and AI-driven health monitoring.

Key Milestones

Timeline Milestone Metric
Q2 2026 Phase I Trial Launch 30 participants enrolled, safety monitoring active
Q4 2026 Platform Beta AI monitoring system deployed, 100 users onboarded
Q1 2027 Phase II Trial Launch 100 participants, full E→C→S→R→P protocol
Q3 2027 FDA Pre-IND Regulatory pathway defined, endpoints agreed
2028 Clinical Program Launch 500+ participants, $7.5M+ revenue
2029 Platform Scale 5,000 participants, $30M+ ARR
2030 Category Leader 10,000+ participants, $60M+ ARR, regulatory approval pathway

Risks & Mitigation

Risk: Clinical Trial Delays

Likelihood: Moderate

Impact: Timeline extension, increased burn

Mitigation:

  • Conservative timeline with 30% buffer
  • Pre-validated biomarkers reduce endpoint risk
  • Clinical operations advisor on team
  • Parallel platform revenue reduces dependency on trial outcomes

Risk: Regulatory Uncertainty

Likelihood: Moderate-High

Impact: Approval pathway complexity

Mitigation:

  • Early FDA engagement via Pre-IND
  • Focus on validated biomarkers (epigenetic clocks)
  • Operate as clinical program while pursuing approval
  • International pathway (EU, Singapore) as backup

Risk: Competition from Big Pharma

Likelihood: Low-Moderate

Impact: Market share pressure

Mitigation:

  • IP moat on dependency gating methodology
  • Category creation = 2-3 year lead
  • Network effects from participant data
  • Pharma more likely acquirer than competitor

Risk: Participant Safety Events

Likelihood: Low

Impact: High (brand, regulatory)

Mitigation:

  • Conservative dosing based on published safety data
  • Continuous monitoring catches issues early
  • Physician oversight for all participants
  • Framework designed to REDUCE risk vs unstructured biohacking

Let's Build the Future of Healthspan

If you're interested in the investment opportunity, we'd love to connect.

Contact Us

or visit mullosaint.com for more research